Multi-Payload Conjugates
Oncology
Pre-clinicalActive
Key Facts
About BrickBio
BrickBio is a private, preclinical-stage biotech based in Cambridge, MA, founded in 2019. The company's core innovation is the Evolved tRNA Localization (ETRNAL) Platform, a mammalian expression system that enables efficient, site-specific incorporation of synthetic amino acids as conjugation handles into any protein backbone. This technology is designed to overcome the heterogeneity and instability of traditional conjugation methods, with initial applications in creating superior ADCs and multi-payload conjugates that are safer and more efficacious. BrickBio operates as a platform company, likely pursuing both internal therapeutic programs and external partnerships.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |